» Articles » PMID: 38067172

UBE3C Facilitates the ER-Associated and Peripheral Degradation of Misfolded CFTR

Overview
Journal Cells
Publisher MDPI
Date 2023 Dec 9
PMID 38067172
Authors
Affiliations
Soon will be listed here.
Abstract

The ubiquitin E3 ligase UBE3C promotes the proteasomal degradation of cytosolic proteins and endoplasmic reticulum (ER) membrane proteins. UBE3C is proposed to function downstream of the RNF185/MBRL ER-associated degradation (ERAD) branch, contributing to the ERAD of select membrane proteins. Here, we report that UBE3C facilitates the ERAD of misfolded CFTR, even in the absence of both RNF185 and its functional ortholog RNF5 (RNF5/185). Unlike RNF5/185, UBE3C had a limited impact on the ubiquitination of misfolded CFTR. UBE3C knockdown (KD) resulted in an additional increase in the functional ∆F508-CFTR channels on the plasma membrane when combined with the RNF5/185 ablation, particularly in the presence of clinically used CFTR modulators. Interestingly, although UBE3C KD failed to attenuate the ERAD of insig-1, it reduced the ERAD of misfolded ∆Y490-ABCB1 and increased cell surface expression. UBE3C KD also stabilized the mature form of ∆F508-CFTR and increased the cell surface level of T70-CFTR, a class VI CFTR mutant. These results suggest that UBE3C plays a vital role in the ERAD of misfolded CFTR and ABCB1, even within the RNF5/185-independent ERAD pathway, and it may also be involved in maintaining the peripheral quality control of CFTR.

Citing Articles

Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways.

Hickey K, Panov A, Whelan E, Schafer T, Mizrak A, Kopito R Proc Natl Acad Sci U S A. 2024; 121(50):e2417390121.

PMID: 39636856 PMC: 11648907. DOI: 10.1073/pnas.2417390121.


Targeting ubiquitination machinery in cystic fibrosis: Where do we stand?.

Okiyoneda T, Borgo C, Bosello Travain V, Pedemonte N, Salvi M Cell Mol Life Sci. 2024; 81(1):271.

PMID: 38888668 PMC: 11335196. DOI: 10.1007/s00018-024-05295-z.


Ligand-based virtual-screening identified a novel CFTR ligand which improves the defective cell surface expression of misfolded ABC transporters.

Taniguchi S, Berenger F, Doi Y, Mimura A, Yamanishi Y, Okiyoneda T Front Pharmacol. 2024; 15:1370676.

PMID: 38666024 PMC: 11043560. DOI: 10.3389/fphar.2024.1370676.

References
1.
Okiyoneda T, Lukacs G . Fixing cystic fibrosis by correcting CFTR domain assembly. J Cell Biol. 2012; 199(2):199-204. PMC: 3471238. DOI: 10.1083/jcb.201208083. View

2.
Keating D, Marigowda G, Burr L, Daines C, Mall M, McKone E . VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018; 379(17):1612-1620. PMC: 6289290. DOI: 10.1056/NEJMoa1807120. View

3.
Leto D, Morgens D, Zhang L, Walczak C, Elias J, Bassik M . Genome-wide CRISPR Analysis Identifies Substrate-Specific Conjugation Modules in ER-Associated Degradation. Mol Cell. 2018; 73(2):377-389.e11. PMC: 6338494. DOI: 10.1016/j.molcel.2018.11.015. View

4.
Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K . Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol. 2004; 164(6):923-33. PMC: 2172283. DOI: 10.1083/jcb.200312018. View

5.
Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, England P, Rodriguez M . Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 2009; 10(11):1250-8. PMC: 2775171. DOI: 10.1038/embor.2009.192. View